{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T15:50:20Z","timestamp":1759333820802,"version":"build-2065373602"},"reference-count":124,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2016,8,1]],"date-time":"2016-08-01T00:00:00Z","timestamp":1470009600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2016,8,1]],"date-time":"2016-08-01T00:00:00Z","timestamp":1470009600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/501100001871","name":"Funda\u00e7\u00e3o para a Ci\u00eancia e a Tecnologia","doi-asserted-by":"publisher","award":["SFRH\/BPD\/92934\/2013"],"award-info":[{"award-number":["SFRH\/BPD\/92934\/2013"]}],"id":[{"id":"10.13039\/501100001871","id-type":"DOI","asserted-by":"publisher"}]},{"name":"FCT","award":["VIH\/SAU\/0021\/2011"],"award-info":[{"award-number":["VIH\/SAU\/0021\/2011"]}]},{"DOI":"10.13039\/501100008530","name":"European Regional Development Fund","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100008530","id-type":"DOI","asserted-by":"crossref"}]},{"name":"North Portugal Regional Operational Programme"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Advanced Drug Delivery Reviews"],"published-print":{"date-parts":[[2016,8]]},"DOI":"10.1016\/j.addr.2015.12.015","type":"journal-article","created":{"date-parts":[[2015,12,28]],"date-time":"2015-12-28T13:00:30Z","timestamp":1451307630000},"page":"20-32","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":18,"special_numbering":"C","title":["Will dapivirine redeem the promises of anti-HIV microbicides? Overview of product design and clinical testing"],"prefix":"10.1016","volume":"103","author":[{"given":"Jos\u00e9","family":"das Neves","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7577-9280","authenticated-orcid":false,"given":"Jo\u00e3o Pedro","family":"Martins","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bruno","family":"Sarmento","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.addr.2015.12.015_bb0005","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1016\/S0140-6736(14)60164-1","article-title":"HIV infection: epidemiology, pathogenesis, treatment, and prevention","volume":"384","author":"Maartens","year":"2014","journal-title":"Lancet"},{"key":"10.1016\/j.addr.2015.12.015_bb0010","unstructured":"US Food and Drug Administration, FDA approves first drug for reducing the risk of sexually acquired HIV infection. Available from URL: http:\/\/www.fda.gov\/NewsEvents\/Newsroom\/PressAnnouncements\/ucm312210.htm (last accessed 20 Nov 2015)."},{"year":"2015","series-title":"Guideline on When to Start Antiretroviral Therapy and on Pre-Exposure Prophylaxis for HIV, Geneva, Switzerland","author":"World Health Organization","key":"10.1016\/j.addr.2015.12.015_bb0015"},{"year":"2014","series-title":"The Gap Report, Geneva, Switzerland","author":"UNAIDS","key":"10.1016\/j.addr.2015.12.015_bb0020"},{"key":"10.1016\/j.addr.2015.12.015_bb0025","doi-asserted-by":"crossref","first-page":"909","DOI":"10.1358\/dof.2011.36.12.1708828","article-title":"A history of microbicides and their current development pipeline","volume":"36","author":"Lynch","year":"2011","journal-title":"Drugs Future"},{"key":"10.1016\/j.addr.2015.12.015_bb0030","doi-asserted-by":"crossref","first-page":"1168","DOI":"10.1126\/science.1193748","article-title":"Effectiveness and safety of tenofovir gel, an antiretroviral microbicide, for the prevention of HIV infection in women","volume":"329","author":"Abdool Karim","year":"2010","journal-title":"Science"},{"key":"10.1016\/j.addr.2015.12.015_bb0035","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1056\/NEJMoa1402269","article-title":"Tenofovir-based preexposure prophylaxis for HIV infection among African women","volume":"372","author":"Marrazzo","year":"2015","journal-title":"N. Engl. J. Med."},{"year":"2015","series-title":"FACTS 001 Phase III trial of pericoital tenofovir 1% gel for HIV prevention in women, CROI \u2013 Conference on Retroviruses and Opportunistic Infections","author":"Rees","key":"10.1016\/j.addr.2015.12.015_bb0040"},{"key":"10.1016\/j.addr.2015.12.015_bb0045","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0125363","article-title":"A phase 1 randomized, open label, rectal safety, acceptability, pharmacokinetic, and pharmacodynamic study of three formulations of tenofovir 1% gel (the CHARM-01 study)","volume":"10","author":"McGowan","year":"2015","journal-title":"PLoS One"},{"key":"10.1016\/j.addr.2015.12.015_bb0050","first-page":"A41","article-title":"The novel non-nucleoside reverse transcriptase inhibitor TMC120 has potent antiretroviral activity after short-term monotherapy in treatment naive, HIV-1 infected subjects","volume":"50","author":"Van't Klooster","year":"2001","journal-title":"Antiviral Res."},{"year":"2001","series-title":"TMC120, a new non-nucleoside reverse transcriptase inhibitor, is a potent antiretroviral in treatment naive, HIV-1 infected subjects, CROI \u2013 Conference on Retrovirus and Opportunistic Infections","author":"Gruzdev","key":"10.1016\/j.addr.2015.12.015_bb0055"},{"key":"10.1016\/j.addr.2015.12.015_bb0060","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1592\/phco.29.3.281","article-title":"Etravirine and rilpivirine: nonnucleoside reverse transcriptase inhibitors with activity against human immunodeficiency virus type 1 strains resistant to previous nonnucleoside agents","volume":"29","author":"Fulco","year":"2009","journal-title":"Pharmacotherapy"},{"key":"10.1016\/j.addr.2015.12.015_bb0065","doi-asserted-by":"crossref","first-page":"245","DOI":"10.2165\/00126839-200405050-00001","article-title":"Correlations between factors determining the pharmacokinetics and antiviral activity of HIV-1 non-nucleoside reverse transcriptase inhibitors of the diaryltriazine and diarylpyrimidine classes of compounds","volume":"5","author":"Lewi","year":"2004","journal-title":"Drugs R&D"},{"key":"10.1016\/j.addr.2015.12.015_bb0070","unstructured":"Johnson & Johnson, Janssen announces expanded collaboration with international partnership for microbicides for development and commercialization of dapivirine for prevention of sexual transmission of HIV. Available from URL: https:\/\/www.jnj.com\/news\/all\/Janssen-Announces-Expanded-Collaboration-with-International-Partnership-for-Microbicides-for-Development-and-Commercialization-of-Dapivirine-for-Prevention-of-Sexual-Transmission-of-HIV (last accessed 20 Nov 2015)."},{"key":"10.1016\/j.addr.2015.12.015_bb0075","doi-asserted-by":"crossref","first-page":"2235","DOI":"10.1016\/S0960-894X(01)00412-7","article-title":"Evolution of anti-HIV drug candidates. Part 3: Diarylpyrimidine (DAPY) analogues","volume":"11","author":"Ludovici","year":"2001","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"10.1016\/j.addr.2015.12.015_bb0080","doi-asserted-by":"crossref","first-page":"954","DOI":"10.1093\/jac\/dki326","article-title":"Long-term, controlled release of the HIV microbicide TMC120 from silicone elastomer vaginal rings","volume":"56","author":"Malcolm","year":"2005","journal-title":"J. Antimicrob. Chemother."},{"key":"10.1016\/j.addr.2015.12.015_bb0085","doi-asserted-by":"crossref","first-page":"289","DOI":"10.4236\/pp.2011.24037","article-title":"Design and development of an in vitro assay for evaluation of solid vaginal dosage forms","volume":"2","author":"Gupta","year":"2011","journal-title":"Pharmacol. Pharm."},{"key":"10.1016\/j.addr.2015.12.015_bb0090","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1016\/j.jpba.2010.01.007","article-title":"Development and validation of a rapid reversed-phase HPLC method for the determination of the non-nucleoside reverse transcriptase inhibitor dapivirine from polymeric nanoparticles","volume":"52","author":"das Neves","year":"2010","journal-title":"J. Pharm. Biomed. Anal."},{"key":"10.1016\/j.addr.2015.12.015_bb0095","doi-asserted-by":"crossref","first-page":"3696","DOI":"10.1002\/jps.24176","article-title":"The use of supersaturation for the vaginal application of microbicides: a case study with dapivirine","volume":"103","author":"Grammen","year":"2014","journal-title":"J. Pharm. Sci."},{"year":"2013","series-title":"Polymeric nanoparticles as carrier systems for antiretroviral agents to be used in the prevention of vaginal HIV transmission, PhD Thesis","author":"das Neves","key":"10.1016\/j.addr.2015.12.015_bb0100"},{"key":"10.1016\/j.addr.2015.12.015_bb0105","doi-asserted-by":"crossref","first-page":"1468","DOI":"10.1007\/s11095-011-0622-3","article-title":"Polymeric nanoparticles affect the intracellular delivery, antiretroviral activity and cytotoxicity of the microbicide drug candidate dapivirine","volume":"29","author":"das Neves","year":"2012","journal-title":"Pharm. Res."},{"key":"10.1016\/j.addr.2015.12.015_bb0110","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1016\/j.ijpharm.2006.06.026","article-title":"Intravaginal ring delivery of the reverse transcriptase inhibitor TMC 120 as an HIV microbicide","volume":"325","author":"Woolfson","year":"2006","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.addr.2015.12.015_bb0115","doi-asserted-by":"crossref","first-page":"4228","DOI":"10.1002\/jps.21331","article-title":"Polyurethane intravaginal ring for controlled delivery of dapivirine, a nonnucleoside reverse transcriptase inhibitor of HIV-1","volume":"97","author":"Gupta","year":"2008","journal-title":"J. Pharm. Sci."},{"key":"10.1016\/j.addr.2015.12.015_bb0120","doi-asserted-by":"crossref","first-page":"917","DOI":"10.1097\/QAD.0b013e32832af57c","article-title":"Sustained release of microbicides by newly engineered vaginal rings","volume":"23","author":"Saxena","year":"2009","journal-title":"AIDS"},{"key":"10.1016\/j.addr.2015.12.015_bb0125","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1016\/j.virusres.2008.01.002","article-title":"Mechanisms of inhibition of HIV replication by non-nucleoside reverse transcriptase inhibitors","volume":"134","author":"Sluis-Cremer","year":"2008","journal-title":"Virus Res."},{"key":"10.1016\/j.addr.2015.12.015_bb0130","doi-asserted-by":"crossref","DOI":"10.1371\/journal.ppat.0020119","article-title":"Potent nonnucleoside reverse transcriptase inhibitors target HIV-1 Gag-Pol","volume":"2","author":"Figueiredo","year":"2006","journal-title":"PLoS Pathog."},{"key":"10.1016\/j.addr.2015.12.015_bb0135","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1177\/135965350501000209","article-title":"Pre-incubation of cell-free HIV-1 group M isolates with non-nucleoside reverse transcriptase inhibitors blocks subsequent viral replication in co-cultures of dendritic cells and T cells","volume":"10","author":"Njai","year":"2005","journal-title":"Antivir. Ther."},{"key":"10.1016\/j.addr.2015.12.015_bb0140","doi-asserted-by":"crossref","first-page":"3684","DOI":"10.1128\/AAC.48.10.3684-3689.2004","article-title":"A series of diaryltriazines and diarylpyrimidines are highly potent nonnucleoside reverse transcriptase inhibitors with possible applications as microbicides","volume":"48","author":"Van Herrewege","year":"2004","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.addr.2015.12.015_bb0145","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1128\/AAC.48.1.337-339.2004","article-title":"In vitro evaluation of nonnucleoside reverse transcriptase inhibitors UC-781 and TMC120-R147681 as human immunodeficiency virus microbicides","volume":"48","author":"Van Herrewege","year":"2004","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.addr.2015.12.015_bb0150","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1128\/AAC.01156-08","article-title":"Inhibition of human immunodeficiency virus type 1 infection by the candidate microbicide dapivirine, a nonnucleoside reverse transcriptase inhibitor","volume":"53","author":"Fletcher","year":"2009","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.addr.2015.12.015_bb0155","doi-asserted-by":"crossref","first-page":"2038","DOI":"10.1093\/jac\/dkt166","article-title":"Diaryltriazine non-nucleoside reverse transcriptase inhibitors are potent candidates for pre-exposure prophylaxis in the prevention of sexual HIV transmission","volume":"68","author":"Ari\u00ebn","year":"2013","journal-title":"J. Antimicrob. Chemother."},{"key":"10.1016\/j.addr.2015.12.015_bb0160","doi-asserted-by":"crossref","first-page":"1901","DOI":"10.1021\/jm040840e","article-title":"In search of a novel anti-HIV drug: multidisciplinary coordination in the discovery of 4-[[4-[[4-[(1E)-2-cyanoethenyl]-2,6-dimethylphenyl]amino]-2-pyrimidinyl]amino]benzonitrile (R278474, rilpivirine)","volume":"48","author":"Janssen","year":"2005","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.addr.2015.12.015_bb0165","doi-asserted-by":"crossref","first-page":"1597","DOI":"10.1097\/00002030-200307250-00003","article-title":"Inhibition of vaginal transmission of HIV-1 in hu-SCID mice by the non-nucleoside reverse transcriptase inhibitor TMC120 in a gel formulation","volume":"17","author":"Di Fabio","year":"2003","journal-title":"AIDS"},{"key":"10.1016\/j.addr.2015.12.015_bb0170","series-title":"Advances in Antiviral Drug Design","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1016\/S1075-8593(06)05006-4","article-title":"The medicinal chemistry of the DATA and DAPY series of HIV-1 non-nucleoside reverse transcriptase inhibitors (NNRTIs)","volume":"5","author":"Heeres","year":"2007"},{"key":"10.1016\/j.addr.2015.12.015_bb0175","doi-asserted-by":"crossref","first-page":"2960","DOI":"10.3390\/v6082960","article-title":"The emerging profile of cross-resistance among the nonnucleoside HIV-1 reverse transcriptase inhibitors","volume":"6","author":"Sluis-Cremer","year":"2014","journal-title":"Viruses"},{"key":"10.1016\/j.addr.2015.12.015_bb0180","doi-asserted-by":"crossref","first-page":"1403","DOI":"10.1128\/AAC.01426-10","article-title":"Human immunodeficiency virus type 1 resistance or cross-resistance to nonnucleoside reverse transcriptase inhibitors currently under development as microbicides","volume":"55","author":"Selhorst","year":"2011","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.addr.2015.12.015_bb0185","doi-asserted-by":"crossref","first-page":"1585","DOI":"10.1097\/QAD.0b013e3283491f89","article-title":"Synergy against drug-resistant HIV-1 with the microbicide antiretrovirals, dapivirine and tenofovir, in combination","volume":"25","author":"Schader","year":"2011","journal-title":"AIDS"},{"key":"10.1016\/j.addr.2015.12.015_bb0190","doi-asserted-by":"crossref","first-page":"751","DOI":"10.1128\/AAC.05821-11","article-title":"In vitro resistance profile of the candidate HIV-1 microbicide drug dapivirine","volume":"56","author":"Schader","year":"2012","journal-title":"Antimicrob. Agents Chemother."},{"issue":"Suppl. 5","key":"10.1016\/j.addr.2015.12.015_bb0195","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1111\/1471-0528.12843","article-title":"Microbicides and their potential as a catalyst for multipurpose sexual and reproductive health technologies","volume":"121","author":"Abdool-Karim","year":"2014","journal-title":"BJOG."},{"key":"10.1016\/j.addr.2015.12.015_bb0200","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1186\/1742-4690-10-113","article-title":"Novel preclinical models of topical PrEP pharmacodynamics provide rationale for combination of drugs with complementary properties","volume":"10","author":"Mesquita","year":"2013","journal-title":"Retrovirology"},{"key":"10.1016\/j.addr.2015.12.015_bb0205","doi-asserted-by":"crossref","first-page":"979","DOI":"10.1016\/j.bcp.2013.08.013","article-title":"Dissimilarities in the metabolism of antiretroviral drugs used in HIV pre-exposure prophylaxis in colon and vagina tissues","volume":"86","author":"To","year":"2013","journal-title":"Biochem. Pharmacol."},{"key":"10.1016\/j.addr.2015.12.015_bb0210","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0131405","article-title":"Expression of genes for drug transporters in the human female genital tract and modulatory effect of antiretroviral drugs","volume":"10","author":"Hijazi","year":"2015","journal-title":"PLoS One"},{"key":"10.1016\/j.addr.2015.12.015_bb0215","doi-asserted-by":"crossref","first-page":"5105","DOI":"10.1128\/AAC.00456-10","article-title":"In vitro evaluation of viability, integrity and inflammation in genital epithelia upon exposure to pharmaceutical excipients and candidate microbicides","volume":"54","author":"Gali","year":"2010","journal-title":"Antimicrob. Agents Chemother."},{"year":"2005","series-title":"TMC120 Blocks HIV-1 Infection in Cellular and Human Cervical Tissue Models, 3rd IAS Conference on HIV Pathogenesis and Treatment","author":"Harman","key":"10.1016\/j.addr.2015.12.015_bb0220"},{"key":"10.1016\/j.addr.2015.12.015_bb0225","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1016\/j.mimet.2011.12.013","article-title":"Testing of viscous anti-HIV microbicides using Lactobacillus","volume":"88","author":"Moncla","year":"2012","journal-title":"J. Microbiol. Methods"},{"key":"10.1016\/j.addr.2015.12.015_bb0230","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1016\/j.ejpb.2005.01.012","article-title":"The evaluation of the local tolerance of vaginal formulations containing dapivirine using the Slug Mucosal Irritation test and the rabbit vaginal irritation test","volume":"60","author":"Dhondt","year":"2005","journal-title":"Eur. J. Pharm. Biopharm."},{"key":"10.1016\/j.addr.2015.12.015_bb0235","doi-asserted-by":"crossref","first-page":"3761","DOI":"10.1128\/AAC.04954-14","article-title":"The sheep as a model of preclinical safety and pharmacokinetic evaluations of candidate microbicides","volume":"59","author":"Holt","year":"2015","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.addr.2015.12.015_bb0240","doi-asserted-by":"crossref","first-page":"909","DOI":"10.1128\/AAC.00330-07","article-title":"Concentrations of dapivirine in the rhesus macaque and rabbit following once daily intravaginal administration of a gel formulation of [14C]dapivirine for 7days","volume":"52","author":"Nuttall","year":"2008","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.addr.2015.12.015_bb0245","doi-asserted-by":"crossref","first-page":"2477","DOI":"10.1093\/jac\/dku160","article-title":"Pre-clinical development of a combination microbicide vaginal ring containing dapivirine and darunavir","volume":"69","author":"Murphy","year":"2014","journal-title":"J. Antimicrob. Chemother."},{"key":"10.1016\/j.addr.2015.12.015_bb0250","series-title":"Drug Delivery and Development of Anti-HIV Microbicides","first-page":"569","article-title":"Socioeconomic and behavioural factors influencing choice, adherence and success of microbicide formulations","author":"Tolley","year":"2014"},{"key":"10.1016\/j.addr.2015.12.015_bb0255","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1016\/j.addr.2015.02.004","article-title":"Acceptability and preferences for vaginal dosage forms intended for prevention of HIV or HIV and pregnancy","volume":"15","author":"Woodsong","year":"2015","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.addr.2015.12.015_bb0260","first-page":"377","article-title":"Development pharmaceutics of microbicide formulations","volume":"17","author":"Garg","year":"2003","journal-title":"Part II: formulation, evaluation, and challenges, AIDS Patient Care STDS"},{"key":"10.1016\/j.addr.2015.12.015_bb0265","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1097\/00126334-200405010-00001","article-title":"Recommendations for the nonclinical development of topical microbicides for prevention of HIV transmission: an update","volume":"36","author":"Lard-Whiteford","year":"2004","journal-title":"J. Acquir. Immune Defic. Syndr."},{"key":"10.1016\/j.addr.2015.12.015_bb0270","doi-asserted-by":"crossref","first-page":"490","DOI":"10.1097\/QAI.0b013e31826f9962","article-title":"State of science of adherence in pre-exposure prophylaxis and microbicide trials","volume":"61","author":"Muchomba","year":"2012","journal-title":"J. Acquir. Immune Defic. Syndr."},{"key":"10.1016\/j.addr.2015.12.015_bb0275","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1016\/j.jadohealth.2007.12.007","article-title":"Adolescent experiences with the vaginal ring","volume":"43","author":"Epstein","year":"2008","journal-title":"J. Adolesc. Health"},{"key":"10.1016\/j.addr.2015.12.015_bb0280","doi-asserted-by":"crossref","first-page":"1015","DOI":"10.3109\/09513590.2013.830100","article-title":"Italian Nuvaring Study Group, Counseling on vaginal delivery of contraceptive hormones: implications for women's body knowledge and sexual health","volume":"29","author":"Nappi","year":"2013","journal-title":"Gynecol. Endocrinol."},{"key":"10.1016\/j.addr.2015.12.015_bb0285","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1016\/j.contraception.2012.08.037","article-title":"Current status of contraceptive vaginal rings","volume":"87","author":"Brache","year":"2013","journal-title":"Contraception"},{"key":"10.1016\/j.addr.2015.12.015_bb0290","doi-asserted-by":"crossref","first-page":"65","DOI":"10.3109\/13625187.2011.637586","article-title":"The CHOICE study: effect of counselling on the selection of combined hormonal contraceptive methods in 11 countries","volume":"17","author":"Bitzer","year":"2012","journal-title":"Eur. J. Contracept. Reprod. Health Care"},{"key":"10.1016\/j.addr.2015.12.015_bb0295","doi-asserted-by":"crossref","first-page":"259","DOI":"10.3109\/13625187.2014.980501","article-title":"Women's experiences, preferences and perceptions regarding vaginal products: results from a cross-sectional web-based survey in Portugal","volume":"20","author":"Palmeira-de-Oliveira","year":"2015","journal-title":"Eur. J. Contracept. Reprod. Health Care"},{"key":"10.1016\/j.addr.2015.12.015_bb0300","doi-asserted-by":"crossref","first-page":"595","DOI":"10.2147\/IJWH.S36282","article-title":"Vaginal rings for delivery of HIV microbicides","volume":"4","author":"Malcolm","year":"2012","journal-title":"Int. J. Womens Health"},{"key":"10.1016\/j.addr.2015.12.015_bb0305","series-title":"Drug Delivery and Development of Anti-HIV Microbicides","first-page":"221","article-title":"Microbicide intravaginal rings","author":"Moss","year":"2014"},{"key":"10.1016\/j.addr.2015.12.015_bb0310","first-page":"62","article-title":"State of the art in intravaginal ring technology for topical prophylaxis of HIV infection","volume":"14","author":"Kiser","year":"2012","journal-title":"AIDS Rev."},{"issue":"Suppl. 1","key":"10.1016\/j.addr.2015.12.015_bb0315","doi-asserted-by":"crossref","first-page":"S30","DOI":"10.1016\/j.antiviral.2010.09.003","article-title":"Advances in microbicide vaginal rings","volume":"88","author":"Malcolm","year":"2010","journal-title":"Antiviral Res."},{"key":"10.1016\/j.addr.2015.12.015_bb0320","doi-asserted-by":"crossref","first-page":"406","DOI":"10.1016\/j.ejps.2012.12.002","article-title":"A silicone elastomer vaginal ring for HIV prevention containing two microbicides with different mechanisms of action","volume":"48","author":"Fetherston","year":"2012","journal-title":"Eur. J. Pharm. Sci."},{"key":"10.1016\/j.addr.2015.12.015_bb0325","doi-asserted-by":"crossref","first-page":"A138","DOI":"10.1089\/aid.2014.5276.abstract","article-title":"Matrix vaginal ring formulations that maintain target in vitro release rates of dapivirine and levonorgestrel (alone or in combination) over 90days","volume":"30","author":"Holt","year":"2014","journal-title":"AIDS Res. Hum. Retroviruses"},{"key":"10.1016\/j.addr.2015.12.015_bb0330","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1016\/j.ejps.2009.11.007","article-title":"Segmented polyurethane intravaginal rings for the sustained combined delivery of antiretroviral agents dapivirine and tenofovir","volume":"39","author":"Johnson","year":"2010","journal-title":"Eur. J. Pharm. Sci."},{"key":"10.1016\/j.addr.2015.12.015_bb0335","doi-asserted-by":"crossref","first-page":"1775","DOI":"10.1007\/s10461-012-0215-0","article-title":"High acceptability of a vaginal ring intended as a microbicide delivery method for HIV prevention in African women","volume":"16","author":"van der Straten","year":"2012","journal-title":"AIDS Behav."},{"key":"10.1016\/j.addr.2015.12.015_bb0340","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1089\/aid.2008.0184","article-title":"Safety and availability of dapivirine (TMC120) delivered from an intravaginal ring","volume":"25","author":"Romano","year":"2009","journal-title":"AIDS Res. Hum. Retroviruses"},{"key":"10.1016\/j.addr.2015.12.015_bb0345","doi-asserted-by":"crossref","first-page":"416","DOI":"10.1097\/QAI.0b013e3181acb536","article-title":"Safety and pharmacokinetics of dapivirine delivery from matrix and reservoir intravaginal rings to HIV-negative women","volume":"51","author":"Nel","year":"2009","journal-title":"J. Acquir. Immune Defic. Syndr."},{"key":"10.1016\/j.addr.2015.12.015_bb0350","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1097\/QAI.0000000000000702","article-title":"Phase 1 safety, pharmacokinetics, and pharmacodynamics of dapivirine and maraviroc vaginal rings: a double-blind randomized trial","volume":"70","author":"Chen","year":"2015","journal-title":"J. Acquir. Immune Defic. Syndr."},{"key":"10.1016\/j.addr.2015.12.015_bb0355","doi-asserted-by":"crossref","first-page":"S3","DOI":"10.1016\/j.antiviral.2013.09.025","article-title":"Development of dapivirine vaginal ring for HIV prevention","volume":"100","author":"Devlin","year":"2013","journal-title":"Antiviral Res."},{"key":"10.1016\/j.addr.2015.12.015_bb0360","doi-asserted-by":"crossref","first-page":"1479","DOI":"10.1097\/QAD.0000000000000280","article-title":"A safety and pharmacokinetic trial assessing delivery of dapivirine from a vaginal ring in healthy women","volume":"28","author":"Nel","year":"2014","journal-title":"AIDS"},{"year":"2012","series-title":"Safety, Acceptability and Pharmacokinetic Assessment (adherence) of Monthly Dapivirine Vaginal Microbicide Rings (Ring-004) for HIV Prevention, CROI \u2013 Conference on Retroviruses and Opportunistic Infections","author":"Nel","key":"10.1016\/j.addr.2015.12.015_bb0365"},{"key":"10.1016\/j.addr.2015.12.015_bb0370","first-page":"355","article-title":"Pharmacokinetics and safety assessment of anti-HIV dapivirine vaginal microbicide rings with multiple dosing","volume":"5","author":"Nel","year":"2014","journal-title":"J. AIDS Clin. Res."},{"year":"2015","series-title":"Local and Systemic Pharmacokinetic Profile of Dapivirine Vaginal Ring-004 when Used Continuously Over Various Periods up to Twelve Weeks, CROI \u2013 Conference on Retroviruses and Opportunistic Infections","author":"Nel","key":"10.1016\/j.addr.2015.12.015_bb0375"},{"key":"10.1016\/j.addr.2015.12.015_bb0380","doi-asserted-by":"crossref","first-page":"A289","DOI":"10.1089\/aid.2014.5655.abstract","article-title":"Baseline characteristics of HIV-negative women enrolled into the ring study-a clinical trial of the dapivirine vaginal ring for HIV-1 prevention","volume":"30","author":"Nel","year":"2014","journal-title":"AIDS Res. Hum. Retroviruses"},{"year":"2015","series-title":"Female Condom Functionality in the Presence of a Vaginal Ring, CROI \u2013 Conference on Retroviruses and Opportunistic Infections","author":"Nel","key":"10.1016\/j.addr.2015.12.015_bb0385"},{"key":"10.1016\/j.addr.2015.12.015_bb0390","doi-asserted-by":"crossref","first-page":"A144","DOI":"10.1089\/aid.2014.5291.abstract","article-title":"Drug-drug interactions between the dapivirine vaginal ring (Ring-004) and miconazole nitrate vaginal capsule (Gyno-Daktarin\u00ae)","volume":"30","author":"Nel","year":"2014","journal-title":"AIDS Res. Hum. Retroviruses"},{"key":"10.1016\/j.addr.2015.12.015_bb0395","doi-asserted-by":"crossref","first-page":"1787","DOI":"10.1007\/s10461-012-0248-4","article-title":"Vaginal ring adherence in sub-Saharan Africa: expulsion, removal, and perfect use","volume":"16","author":"Montgomery","year":"2012","journal-title":"AIDS Behav."},{"key":"10.1016\/j.addr.2015.12.015_bb0400","doi-asserted-by":"crossref","first-page":"1185","DOI":"10.1016\/S1473-3099(14)70888-6","article-title":"Highlights from the inaugural HIVR4P conference","volume":"14","author":"Kirby","year":"2014","journal-title":"Lancet Infect. Dis."},{"key":"10.1016\/j.addr.2015.12.015_bb0405","unstructured":"Microbicide Trials Network, MTN-020 - ASPIRE. Available from URL: http:\/\/www.mtnstopshiv.org\/news\/studies\/mtn020 (last accessed 20 Nov 2015)."},{"key":"10.1016\/j.addr.2015.12.015_bb0410","unstructured":"International Partnership for Microbicides, The Ring Study. Avaliable from URL: http:\/\/www.ipmglobal.org\/the-ring-study (last accessed 20 Nov 2015)."},{"key":"10.1016\/j.addr.2015.12.015_bb0415","unstructured":"Microbicide Trials Network, MTN-025. Avaliable from URL: http:\/\/www.mtnstopshiv.org\/studies\/5919 (last accessed 20 Nov 2015)."},{"key":"10.1016\/j.addr.2015.12.015_bb0420","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.ijpharm.2006.03.012","article-title":"Gels as vaginal drug delivery systems","volume":"318","author":"das Neves","year":"2006","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.addr.2015.12.015_bb0425","doi-asserted-by":"crossref","first-page":"88","DOI":"10.2174\/157016212799304599","article-title":"Formulation and delivery of microbicides","volume":"10","author":"Agashe","year":"2012","journal-title":"Curr. HIV Res."},{"key":"10.1016\/j.addr.2015.12.015_bb0430","first-page":"87","article-title":"Annex 2. Stability testing of active pharmaceutical ingredients and finished pharmaceutical products","volume":"953","author":"World Health Organization","year":"2009","journal-title":"World Health Organ. Tech. Rep. Ser."},{"key":"10.1016\/j.addr.2015.12.015_bb0435","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1097\/QAI.0b013e31802bb35f","article-title":"Dose-ranging phase 1 study of TMC120, a promising vaginal microbicide, in HIV-negative and HIV-positive female volunteers","volume":"44","author":"Jespers","year":"2007","journal-title":"J. Acquir. Immune Defic. Syndr."},{"key":"10.1016\/j.addr.2015.12.015_bb0440","doi-asserted-by":"crossref","first-page":"3768","DOI":"10.1007\/s11095-015-1738-7","article-title":"Pharmacodynamic activity of dapivirine and maraviroc single entity and combination topical gels for HIV-1 prevention","volume":"32","author":"Dezzutti","year":"2015","journal-title":"Pharm. Res."},{"key":"10.1016\/j.addr.2015.12.015_bb0445","first-page":"29","article-title":"Current strategies for anti-retroviral drug transport across vaginal and rectal epithelium","volume":"105","author":"Kelly","year":"2014","journal-title":"Gattefoss\u00e9 Bull. Tech."},{"key":"10.1016\/j.addr.2015.12.015_bb0450","first-page":"1531","article-title":"Safety, tolerability, and systemic absorption of dapivirine vaginal microbicide gel in healthy","volume":"23","author":"Nel","year":"2009","journal-title":"HIV-negative women, AIDS"},{"key":"10.1016\/j.addr.2015.12.015_bb0455","doi-asserted-by":"crossref","first-page":"1181","DOI":"10.1089\/aid.2009.0227","article-title":"Pharmacokinetic assessment of dapivirine vaginal microbicide gel in healthy, HIV-negative women","volume":"26","author":"Nel","year":"2010","journal-title":"AIDS Res. Hum. Retroviruses"},{"key":"10.1016\/j.addr.2015.12.015_bb0460","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1097\/QAI.0b013e3181e3293a","article-title":"Pharmacokinetics of 2 dapivirine vaginal microbicide gels and their safety vs. hydroxyethyl cellulose-based universal placebo gel","volume":"55","author":"Nel","year":"2010","journal-title":"J. Acquir. Immune Defic. Syndr."},{"key":"10.1016\/j.addr.2015.12.015_bb0465","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1089\/aid.2013.0170","article-title":"A randomized male tolerance study of dapivirine gel following multiple topical penile exposures (MTN 012\/IPM 010)","volume":"30","author":"Cranston","year":"2014","journal-title":"AIDS Res. Hum. Retroviruses"},{"year":"2012","series-title":"Daily Use of Two Dapivirine Vaginal Gels in the United States: Adherence and Acceptability, 2012 International Microbicides Conference","author":"Montgomery","key":"10.1016\/j.addr.2015.12.015_bb0470"},{"key":"10.1016\/j.addr.2015.12.015_bb0475","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0048328","article-title":"Is wetter better? An evaluation of over-the-counter personal lubricants for safety and anti-HIV-1 activity","volume":"7","author":"Dezzutti","year":"2012","journal-title":"PLoS One"},{"key":"10.1016\/j.addr.2015.12.015_bb0480","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1016\/j.contraception.2006.09.003","article-title":"Fourteen-day safety and acceptability study of the universal placebo gel","volume":"75","author":"Schwartz","year":"2007","journal-title":"Contraception"},{"key":"10.1016\/j.addr.2015.12.015_bb0485","doi-asserted-by":"crossref","first-page":"A155","DOI":"10.1089\/aid.2014.5320.abstract","article-title":"Characterization of a dapivirine impurity found in dapivirine gel product during storage","volume":"30","author":"Derrick","year":"2014","journal-title":"AIDS Res. Hum. Retroviruses"},{"key":"10.1016\/j.addr.2015.12.015_bb0490","doi-asserted-by":"crossref","first-page":"2069","DOI":"10.1002\/jps.23577","article-title":"Vaginal films for drug delivery","volume":"102","author":"Machado","year":"2013","journal-title":"J. Pharm. Sci."},{"key":"10.1016\/j.addr.2015.12.015_bb0495","first-page":"27","article-title":"Microbicide dosage forms","volume":"383","author":"Rohan","year":"2014","journal-title":"Curr. Top. Microbiol. Immunol."},{"key":"10.1016\/j.addr.2015.12.015_bb0500","series-title":"Drug Delivery and Development of Anti-HIV Microbicides","first-page":"291","article-title":"Vaginal microbicide films","author":"Rohan","year":"2014"},{"issue":"Suppl. 1","key":"10.1016\/j.addr.2015.12.015_bb0505","doi-asserted-by":"crossref","first-page":"S19","DOI":"10.1016\/j.antiviral.2010.09.010","article-title":"Advances in development, scale-up and manufacturing of microbicide gels, films, and tablets","volume":"88","author":"Garg","year":"2010","journal-title":"Antiviral Res."},{"key":"10.1016\/j.addr.2015.12.015_bb0510","doi-asserted-by":"crossref","first-page":"31901","DOI":"10.1063\/1.4793598","article-title":"Transient swelling, spreading, and drug delivery by a dissolved anti-HIV microbicide-bearing film","volume":"25","author":"Tasoglu","year":"2013","journal-title":"Phys. Fluids"},{"key":"10.1016\/j.addr.2015.12.015_bb0515","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1080\/14681990310001609859","article-title":"The ins and outs of vaginal lubrication","volume":"18","author":"Levin","year":"2003","journal-title":"Sex. Rel. Ther."},{"key":"10.1016\/j.addr.2015.12.015_bb0520","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1007\/s13346-011-0022-6","article-title":"Development and characterization of a vaginal film containing dapivirine, a non-nucleoside reverse transcriptase inhibitor (NNRTI), for prevention of HIV-1 sexual transmission","volume":"1","author":"Akil","year":"2011","journal-title":"Drug Deliv. Transl. Res."},{"key":"10.1016\/j.addr.2015.12.015_bb0525","doi-asserted-by":"crossref","first-page":"1533","DOI":"10.1021\/mp4007024","article-title":"Increased dapivirine tissue accumulation through vaginal film codelivery of dapivirine and tenofovir","volume":"11","author":"Akil","year":"2014","journal-title":"Mol. Pharm."},{"key":"10.1016\/j.addr.2015.12.015_bb0530","doi-asserted-by":"crossref","first-page":"458","DOI":"10.1007\/s11095-014-1474-4","article-title":"Formulation and characterization of polymeric films containing combinations of antiretrovirals (ARVs) for HIV prevention","volume":"32","author":"Akil","year":"2015","journal-title":"Pharm. Res."},{"key":"10.1016\/j.addr.2015.12.015_bb0535","doi-asserted-by":"crossref","DOI":"10.1097\/QAI.0000000000000897","article-title":"A Phase 1 trial to assess the safety, acceptability, pharmacokinetics and pharmacodynamics of a novel dapivirine vaginal film","author":"Bunge","year":"2016","journal-title":"J. Acquir. Immune Defic. Syndr."},{"key":"10.1016\/j.addr.2015.12.015_bb0540","doi-asserted-by":"crossref","first-page":"1207","DOI":"10.1089\/jwh.2010.2476","article-title":"Acceptability of vaginal film, soft-gel capsule, and tablet as potential microbicide delivery methods among African women","volume":"20","author":"Nel","year":"2011","journal-title":"J. Womens Health (Larchmt.)"},{"key":"10.1016\/j.addr.2015.12.015_bb0545","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1016\/j.ijpharm.2009.12.042","article-title":"Freeze-dried, mucoadhesive system for vaginal delivery of the HIV microbicide, dapivirine: optimisation by an artificial neural network","volume":"388","author":"Woolfson","year":"2010","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.addr.2015.12.015_bb0550","doi-asserted-by":"crossref","first-page":"21","DOI":"10.2174\/157341211794708703","article-title":"Development and validation of a HPLC method for simultaneous determination of dapivirine and DS003 in combination microbicide tablet","volume":"7","author":"Gupta","year":"2011","journal-title":"Curr. Pharm. Anal."},{"key":"10.1016\/j.addr.2015.12.015_bb0555","doi-asserted-by":"crossref","first-page":"309","DOI":"10.2174\/1567201811310030007","article-title":"Development of solid dispersion systems of dapivirine to enhance its solubility","volume":"10","author":"Gorajana","year":"2013","journal-title":"Curr. Drug Deliv."},{"key":"10.1016\/j.addr.2015.12.015_bb0560","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1016\/j.contraception.2012.10.018","article-title":"A modified SILCS contraceptive diaphragm for long-term controlled release of the HIV microbicide dapivirine","volume":"88","author":"Major","year":"2013","journal-title":"Contraception"},{"key":"10.1016\/j.addr.2015.12.015_bb0565","doi-asserted-by":"crossref","first-page":"2793","DOI":"10.1021\/mp4002365","article-title":"In vitro and ex vivo evaluation of polymeric nanoparticles for vaginal and rectal delivery of the anti-HIV drug dapivirine","volume":"10","author":"das Neves","year":"2013","journal-title":"Mol. Pharm."},{"key":"10.1016\/j.addr.2015.12.015_bb0570","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/j.actbio.2015.02.007","article-title":"Precise engineering of dapivirine-loaded nanoparticles for the development of anti-HIV vaginal microbicides","volume":"18","author":"das Neves","year":"2015","journal-title":"Acta Biomater."},{"key":"10.1016\/j.addr.2015.12.015_bb0575","doi-asserted-by":"crossref","first-page":"1834","DOI":"10.1007\/s11095-013-1287-x","article-title":"Biodistribution and pharmacokinetics of dapivirine-loaded nanoparticles after vaginal delivery in mice","volume":"31","author":"das Neves","year":"2014","journal-title":"Pharm. Res."},{"key":"10.1016\/j.addr.2015.12.015_bb0580","doi-asserted-by":"crossref","first-page":"1797","DOI":"10.1128\/AAC.01096-08","article-title":"Reverse transcriptase inhibitors as potential colorectal microbicides","volume":"53","author":"Herrera","year":"2009","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.addr.2015.12.015_bb0585","series-title":"Drug Delivery and Development of Anti-HIV Microbicides","first-page":"549","article-title":"Regulatory issues pertaining to microbicide development","author":"Arterburn","year":"2014"},{"year":"2014","series-title":"Guidance for Industry Vaginal Microbicides: Development for the Prevention of HIV Infection","author":"Food","key":"10.1016\/j.addr.2015.12.015_bb0590"},{"key":"10.1016\/j.addr.2015.12.015_bb0595","first-page":"137","article-title":"Developing regulatory strategy for microbicides","volume":"383","author":"Nardi","year":"2014","journal-title":"Curr. Top. Microbiol. Immunol."},{"key":"10.1016\/j.addr.2015.12.015_bb0600","first-page":"22","article-title":"Clean-room LSR molding cell for new approach to HIV\/AIDS prevention","volume":"60","author":"Naitove","year":"2014","journal-title":"Plast. Technol."},{"key":"10.1016\/j.addr.2015.12.015_bb0605","series-title":"Drug Delivery and Development of Anti-HIV Microbicides","first-page":"535","article-title":"Microbicide formulation development: scale-up, affordability, and intellectual property issues","author":"Friend","year":"2014"},{"key":"10.1016\/j.addr.2015.12.015_bb0610","unstructured":"QPharma AB, QPharma AB enters agreement with International Partnership for Microbicides for future manufacture of dapivirine vaginal ring for HIV prevention. Available from URL: www.qpharma.com\/20150622%20DPV%20Launch%20FINAL.pdf (last accessed 20 Nov 2015)."},{"key":"10.1016\/j.addr.2015.12.015_bb0615","series-title":"Annual Report","article-title":"The promise of prevention for women","author":"International Partnership for Microbicides","year":"2014"},{"key":"10.1016\/j.addr.2015.12.015_bb0620","first-page":"153","article-title":"Preparing for microbicide introduction, rollout, and sustained access","volume":"383","author":"Woodsong","year":"2014","journal-title":"Curr. Top. Microbiol. Immunol."}],"container-title":["Advanced Drug Delivery Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0169409X15300211?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0169409X15300211?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,30]],"date-time":"2025-09-30T04:40:11Z","timestamp":1759207211000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0169409X15300211"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,8]]},"references-count":124,"alternative-id":["S0169409X15300211"],"URL":"https:\/\/doi.org\/10.1016\/j.addr.2015.12.015","relation":{},"ISSN":["0169-409X"],"issn-type":[{"type":"print","value":"0169-409X"}],"subject":[],"published":{"date-parts":[[2016,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Will dapivirine redeem the promises of anti-HIV microbicides? Overview of product design and clinical testing","name":"articletitle","label":"Article Title"},{"value":"Advanced Drug Delivery Reviews","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.addr.2015.12.015","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2015 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}